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Ovine recombinant PrP as an inhibitor of ruminant prion
propagation in vitro
Rob G. Workmana, Ben C. Maddisonb, and Kevin C. Gougha
aSchool of Veterinary Medicine and Science, The University of Nottingham, Sutton
Bonington, Leicestershire, UK;
bADAS, The University of Nottingham, Sutton Bonington, Leicestershire, UK
ABSTRACT. Prion diseases are fatal and incurable neurodegenerative diseases of humans and
animals. Despite years of research, no therapeutic agents have been developed that can
effectively manage or reverse disease progression. Recently it has been identified that
recombinant prion proteins (rPrP) expressed in bacteria can act as inhibitors of prion replication
within the in vitro prion replication system protein misfolding cyclic amplification (PMCA).
Here, within PMCA reactions amplifying a range of ruminant prions including distinct Prnp
genotypes/host species and distinct prion strains, recombinant ovine VRQ PrP displayed
consistent inhibition of prion replication and produced IC50 values of 122 and 171 nM for
ovine scrapie and bovine BSE replication, respectively. These findings illustrate the therapeutic
potential of rPrPs with distinct TSE diseases.
KEYWORDS. BSE, PMCA, prion diseases, protein inhibitors, recombinant PrP, Scrapie,
therapeutics
INTRODUCTION
Prion diseases, also known as transmissible
spongiform encephalopathies (TSEs), are fatal
neurodegenerative diseases that affect humans
and animals. Examples include scrapie in sheep,
bovine spongiform encephalopathy (BSE) in
cattle and Creutzfelt Jakob disease (CJD) in
humans. The central event in these diseases is
the conversion of cellular prion protein (PrPC)
into the pathogenic isoform PrPSc.1 However,
the exact mechanism of conversion and the
cause of pathogenesis remains unclear.
It is proposed that PrPSc propagates by a
template conversion model, whereby PrPC is
converted into further copies of PrPSc indepen-
dently of nucleic acids.2 Through this mecha-
nism PrPSc spreads throughout the central
nervous system (CNS) of the host, eventually
leading to the development of clinical
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symptoms.3 The symptoms themselves are
characterized by neuropathy and loss of cogni-
tive function leading to death.4 These diseases
are classically associated with long asymptom-
atic incubation periods.5
The pursuit of therapeutics for prion diseases
has been a research priority for over 2 decades,
especially following the BSE epidemic in the
United Kingdom from the mid-1980s to
1990s.6 This epidemic resulted in the transmis-
sion of BSE to humans, leading to the emer-
gence of variant CJD (vCJD).7 A recent study
has suggested that 1 in 2000 individuals may
be carriers of the BSE PrPSc protein in the UK,
highlighting the potential for iatrogenic trans-
mission.8 Approaches to the development of
therapeutics have included pharmaceuticals,
immunotherapeutics, protein and peptide inhib-
itors, immunopotentiators and many others.4,6,9
A number of compounds have even been taken
as far as clinical studies, including pentosan
polysulphate and quinacrine.10-12 However,
neither of these compounds have been found to
be effective in reducing disease progression in
clinically-affected patients.12-14
Recently it was reported that heterologous
recombinant prion proteins (rPrPs) can act as
inhibitors of prion amplification in vitro and in
vivo, highlighting the potential use of rPrPs as
therapeutic agents for controlling or slowing
the development of prion replication.15,16
Here, we use the protein misfolding cyclic
amplification (PMCA) assay as an in vitro
model for prion replication. PMCA is a tech-
nique pioneered by Soto and colleagues17 and
allows the amplification of minute quantities of
PrPSc when seeded into a PrPC substrate and
being subjected to rounds of incubation and
sonication, this can include the periodic replen-
ishment of PrPC substrate in a process termed
serial PMCA (sPMCA).18 Using PMCA, rPrPs
representing different ovine Prnp genotypes
were tested as inhibitors of scrapie and BSE
replication. In terms of ovine Prnp genotype, it
is well documented that the VRQ genotype
(codons 136, 154 and 171 of Prnp, respec-
tively) is associated with high susceptibility to
classical scrapie, and ARR is associated with
high resistance.19 The ARQ genotype is suscep-
tible to classical scrapie and different
genotypes may be infected with different prion
strains.20 The strains that were amplified
included ovine TSEs with distinct prion strains,
in hosts with distinct Prnp genotypes, and
replication in PrPC substrate with distinct
Prnp genotype (combinations are summarised
in Table 1).
RESULTS
Bacterially expressed recombinant prion
proteins were cloned, expressed and purified by
immobilised metal affinity chromatography
(IMAC) to the level of a single protein band on
an SDS-PAGE gel (Fig. 1). Typical yields of
the refolded recombinant proteins were 12 mg/L
of culture.
rPrP proteins were assessed as inhibitors
within in vitro PMCA reactions. TSE sam-
ples used are detailed in (Table 1). IC50 val-
ues were calculated for rVRQ, rARQ and
rARR proteins when inhibiting the replica-
tion of a single ARQ/VRQ classical scrapie
isolate (Fig. 2). rVRQ was the strongest
inhibitor with a mean IC50, when calculated
using the dot blot analysis method, of
122 nM, followed by rARQ (IC50 of 288
nM) and rARR (IC50 of 505 nM). The anal-
ysis of PMCA products inhibited by
1200 nM rVRQ or where no spike was pres-
ent demonstrated that the dot blot method
was detecting PrPSc and no residual PrPC
signals were present (Fig. 2). Reanalysis of
all samples by western blot further demon-
strated the specific analysis of PrPSc and pro-
duced IC50 values that gave the same
relative efficacy for the rVRQ, rARQ and
rARR inhibition: 85, 200 and 515 nM,
respectively (Fig. 2 and data not shown).
It was then determined whether the confor-
mation of the rVRQ was required for inhibi-
tion to occur. Heat-denatured rPrP was used
at 1200 nM along with non-denatured rVRQ
and both inhibited replication of scrapie
PrPSc. There was a trend for the denatured
rVRQ to show less inhibition but this was not
significantly different (p D 0.08; Fig. 3).
Addition of a control protein (bovine serum
albumin; BSA) to the reactions at 1200 nM
did not inhibit replication which was only
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inhibited by 0.08% (average of triplicate
analysis) in the presence of this protein
(unpaired Student’s t-test analysis gave a p
value of 0.98; data not shown).
It was then determined whether rVRQ
could bind scrapie PrPSc. After incubation
with scrapie-affected brain, beads coated in
rVRQ could seed PMCA reactions and this
was not the case for beads lacking the
recombinant protein (Fig. 4). On average,
beads coated in rVRQ captured 32% of the
PMCA seeding capability in the brain
homogenate, without rVRQ only 6% of seed-
ing activity was recovered.
A possible explanation for the greater effi-
cacy of rVRQ as an inhibitor of the replica-
tion of this ARQ/VRQ classical scrapie
isolate is the homologous sequence between
the inhibiting protein, the PrPSc seed and/or
PrPC substrate used for amplification (VRQ/
TABLE 1. Prion disease isolates used in this study.
Strain Type Sample Number
Prnp genotype
of host
Prnp genotype of
PMCA substrate
Classical Scrapie PG1361/05 VRQ/ARQ VRQ/VRQ
Classical Scrapie PG1563/02 VRQ/VRQ VRQ/VRQ
G338 Scrapie MC136477 VRQ/VRQ VRQ/VRQ
G338 Scrapie MC136553 VRQ/VRQ VRQ/VRQ
Apl338/Apl338ii Scrapie MC141403 VRQ/VRQ VRQ/VRQ
Apl338/Apl338ii Scrapie MC141404 VRQ/VRQ VRQ/VRQ
CH1641 Scrapie J2935 AHQ/ARQ AHQ/AHQ
Ovine BSE PG0392/04 ARQ/ARQ VRQ/VRQ
Ovine BSE PG1693/03 ARQ/ARQ VRQ/VRQ
Bovine BSE SE1929/0749 Bovine Bovine
Bovine BSE SE1945/0035 Bovine Bovine
Bovine BSE SE1762/0013 Bovine Bovine
Classical scrapie and BSE infected brain material were field cases from the APHA (Addlestone, Surrey, UK). BSE samples SE1929/0749,
SE1945/0035 and SE1762/0013 were pools of multiple isolates. Ovine BSE samples originated from ovine BSE challenges of sheep (APHA).
CH1641 scrapie isolates were a gift from Professor N. Hunter, The Roslin Institute, (University of Edinburgh). Apl338ii and G338 scrapie brain
tissue was isolated from a transgenic mouse bioassay (transgenic for ovine VRQ Prnp).29
FIGURE 1. Ovine PrPs rVRQ, rARQ and rARR purified by IMAC. A) Purification of rVRQ. Lane 1:
rVRQ from urea solubilised washed inclusion body. Lane 2 to 9: elution fractions. B) Purification of
rARQ. Lanes 1-6: elution fractions. C) Purification of rARR. Lanes 1-6: elution fractions. The inclu-
sion body sample was 4.5 mL of a total of 30 mL produced from 1 L of bacterial culture. Each elu-
tion fraction is 4.5 mL of 5 mL total volume for each fraction. Molecular mass markers are indicated.
OVINE RECOMBINANT PRP AS AN INHIBITOR OF PRION PROPAGATION 267
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 N
ott
ing
ha
m]
 at
 02
:52
 13
 D
ec
em
be
r 2
01
7 
VRQ). To determine whether absolute
sequence identity was a requirement for the
inhibition of prion replication, the 2 most
effective inhibitors as determined by IC50,
rVRQ and rARQ, were applied to bovine
BSE PMCA amplification (Fig. 5). The mean
IC50 values were 171 nM for rVRQ and
366 nM for rARQ.
FIGURE 2. Inhibition of ovine prion replication with distinct rPrPs. A single classical scrapie sample
(PG1361/05) was amplified in triplicates by PMCA for one round using a VRQ PrPC substrate.
PMCA reaction products amplified in the presence or absence of rVRQ, rARR or rARQ recombi-
nant proteins in a dilution series of 0-1200 nM were each analyzed in duplicate by dot blot (repre-
sentative blots are shown in A). Protease-resistant PrPSc was detected with SHa31. Blots were
analyzed using ImageJ software and signals expressed as the percentage of the 0 nM inhibitor
control signal. Inhibition with 1200 nM of rVRQ was used as a 100% inhibition control and used to
calculate the background blot signals. PrPC substrate controls are also shown further illustrating
the removal of all PrPC by the PK-digestion procedure. Values were plotted using GraphPad Prism.
Inhibition occurred with mean IC50 values of 122 nM for rVRQ, 228 nM for rARQ and 505 nM for
rARR calculated from 3 separate experiments (B). All amplification products were also analyzed by
western blot (using identical conditions to the dot blots with the exception that 6.7 mL of PK
digested PMCA reaction was analyzed) and an example for VRQ inhibition is shown (C), the con-
centration of rVRQ inhibitor is indicated. All blots also contained analysis, in triplicate, of PrPC sub-
strate that again demonstrated the complete removal of PrPC signals (shown for the first blot only).
Densitometry data from the blots is shown (D) and was used to calculate an IC50 value for rVRQ of
85 nM. Molecular mass markers are indicated.
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VRQ rPrP was then tested as an inhibitor of
the amplification of isolates over 5 rounds of
sPMCA, different scrapie strains were analyzed
as well as ovine and bovine BSE. (Table 1).
Scrapie samples included classical ovine
scrapie isolates, Apl338/Apl338ii and G338 scra-
pie strains derived from tg338 transgenic
mice29 (both amplified in VRQ substrate),
CH1641 scrapie (in an ARQ/AHQ host and
amplified in an AHQ substrate), ovine BSE (in
an ARQ/ARQ host and amplified in a VRQ
substrate) and bovine BSE (amplified in bovine
substrate) (Table 1). These samples were
chosen because of their efficient amplification
over the course of 5 d of sPMCA. PMCA was
performed in the presence of rVRQ at 400 nM
which consistently inhibited prion amplifica-
tion (Fig. 6).
DISCUSSION
Using PMCA as an in vitro model for prion
replication, ovine PrP was shown to inhibit the
replication of VRQ/ARQ scrapie prion in
VRQ/VRQ substrate with rVRQ, rARQ and
rARR producing mean IC50 values of 122, 288
and 505, respectively (calculated from dot blot
analysis of PMCA products). For the inhibition
of bovine BSE replication in bovine substrate,
the mean IC50 values were 171 nM for rVRQ
and 366 nM for rARQ. These data indicate that
VRQ was the stronger inhibitor and could
inhibit prion replication in the absence of abso-
lute sequence identity with substrate or seed
PrP.
Effective concentration 50% (EC50) values
have been reported by Yuan et al. when analyz-
ing inhibition with rPrP homologous to the seed
and substrate PrP sequence.15 The models used
were for human rPrP23–231 (129V) inhibition
of iCJDVV2 (iatrogenic CJD, PRNP valine 129
homozygous) amplification in TgWV murine
(transgenic for human 129V PRNP) substrate,
where the approximate EC50 value was
60 nM, and mouse rPrP23–231 inhibition of
mouse PrPSc (strain 139A) amplification in
mouse brain homogenate where the approxi-
mate EC50 value was 120 nM. These figures
are similar to the IC50 values determined in the
present study for rVRQ inhibition of homolo-
gous genotype seed/substrate.
Here, inhibition was also demonstrated with
PrPSc seeds from bovine and ovine hosts,
including ovine hosts with distinct Prnp geno-
types, and with distinct prion strains, and also
when amplification was within substrate with
different Prnp genotypes (Table 1, Fig. 6).
These data indicate that rVRQ may act as a
‘universal inhibitor’ of ruminant prion replica-
tion in vitro.
FIGURE 3. Both native and denatured rVRQ
inhibit prion replication. PMCA amplification of a
scrapie isolate (PG1361/05) was performed in
triplicate in the presence of 1200 nM of rVRQ
with or without denaturation or in the absence of
any rPrP (as indicated). 6.7 mL of PK digested
PMCA reaction was analyzed by western blot-
ting using monoclonal antibody SHa31 (A). Fol-
lowing densitometry, signals were expressed as
the percent inhibition, calculated using the no
rPrP controls as 100% amplification (B). No sig-
nificant difference in the inhibition levels
between rVRQ and denatured rVRQ was
observed (unpaired Student’s t-test, p D 0.08).
Molecular mass markers are indicated.
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The mechanism of rPrP inhibition remains
unresolved. In terms of the binding ability of
rPrP, Yuan et al.15 demonstrated that human
rPrP23–231 bound to PrPSc (iCJD) but not
PrPC, and Meier et al. report that murine rPrP
binds murine adapted scrapie PrPSc.21 The pres-
ent study also demonstrates that rVRQ bound to
ovine scrapie PrPSc which was then able to seed
PMCA reactions. It has been previously sug-
gested that rPrP inhibition is species specific
and correlates to sequence similarity.22 Here
the majority of scrapie strains and ovine BSE
used were amplified in a VRQ/VRQ substrate
(Table 1) and inhibited with rVRQ. Sequence
similarity between inhibitor and seed/substrate
may well be important and the most effective
inhibition was seen with rVRQ inhibition of
seed/substrate with homologous Prnp geno-
type. However, the presented data also indi-
cates that the mechanism for inhibition is not
wholly dependent on such sequence similarity.
Both rVRQ and rARQ proteins inhibited
bovine BSE amplification in bovine brain
homogenate substrate, suggesting that the
inhibitory activity of these proteins may be
independent of sequence similarity. This is fur-
ther supported by experiments with rVRQ
inhibiting different TSE isolates/strains and in
prion amplification reactions with substrates of
heterologous genotypes. Here, it was also
shown that heat denatured rVRQ could inhibit
ovine scrapie replication indicating that rPrP
conformation is not a major influence on the
mechanism of inhibition. It may suggest that
internal unstructured PrP amino acid linear
sequences are involved in interactions with
PrPSc that facilitate inhibition of prion replica-
tion. However, this assumes that incubation of
the denatured rPrP at 378C during PMCA does
not promote full refolding of rVRQ. Using
mouse and hamster prion replication models,
internal rPrP peptides have previously been
shown to inhibit prion replication and such pep-
tides include the region that in sheep contains
the 136 polymorphism (hamster PrP residues
109-141).23,24 These studies also show that inhi-
bition by this peptide is effective across species
where there is not absolute amino acid sequence
identity.24 This supports other studies using cell-
FIGURE 4. rVRQ binds to PrPSc. Beads were
coated with rVRQ (rVRQ-beads capture) or had
no rPrP present (bead capture) and were then
incubated with brain homogenate from a scra-
pie-affected sheep (PG1361/05). Following
extensive washing, the beads were used to
seed PMCA reactions along with beads that
had not been incubated with any brain sample
(beads only). PMCA products were digested
with PK and analyzed for PrPSc with antibody
SHa31 (A). Following densitometry, signals
were expressed as the percent amplification
compared with a control reaction directly spiked
with an equivalent level of PrPSc (PrPSc seed)
as 100% amplification after the background sig-
nals for beads only reactions were removed (B).
The difference in PMCA seeding between
beads with and without rVRQ was significantly
different (unpaired Student’s t-test, p D 0.03).
Molecular mass markers are indicated.
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free conversion reactions where heterologous
PrPC has been demonstrated to effectively
inhibit homologous PrPC to PrPSc conversion.25
If the analogous linear stretch of residues within
rPrP described by Chabray and colleagues23,24
influences binding of ovine rPrP to ruminant
PrPSc and inhibition of replication, then the 136
polymorphism may influence the efficacy of this
process but inhibition of differing PrPSc primary
sequences should be possible, as appears to be
the case in the present study.
The inhibitory mechanism of rPrPs may be
in part due to the lack of secondary modifica-
tions. Different glycosylation states of PrP can
selectively affect prion strain amplification.26
rPrPs then may act as competitive, but less con-
version efficient substrates due to the lack of
secondary modifications.15,16,21 This may be
aided by the concentration of inhibitor used
here (400 nM) and by Yuan et al.15 (200 nM),
which are far greater than physiological con-
centrations of PrPC (»13 nM in 10% ovine
brain homogenate, calculated from the values
reported elsewhere27). The reported data from
an in vitro model indicates that rVRQ is a ther-
apeutic candidate that requires examination in
vivo using transgenic mice. In a recent study,
RML-chandler scrapie disease progression in
mice was increasingly delayed in response to
increasing doses of hamster rPrP. This study
suggested that the stoichiometry of host PrPC to
rPrP could be an important factor in the inhibi-
tory mechanism and importantly, demonstrated
that rPrPs have therapeutic effects in vivo.16
Why the rVRQ protein acts as an inhibitor
of replication for a range of TSE isolates
and strains is unexplained, but PrP proteins
containing the ovine Q171 polymorphism are
known to act as superior amplification sub-
strates even to other prion types like BSE
FIGURE 5. Inhibition of bovine BSE prion replication with rPrPs. Bovine BSE (SE1762/0013) was
amplified in triplicates for one round in bovine PrPC substrate. Dot blots of PMCA reaction products
amplified in the presence or absence of rVRQ and rARQ in a dilution series of 0-800 nM are shown
for representative blots (A). Products were digested with PK and 0.83 mL of the PMCA reaction
analyzed by dot blot. PrPSc was detected with monoclonal antibody SHa31. Blots were analyzed
using ImageJ software and signals expressed as the percent of the 0 nM inhibitor control. Inhibition
with 1200 nM of rVRQ was used as a 100% inhibition control and used to calculate the background
blot signals. A PrPSc positive control sample and a PrPC substrate were also analyzed on each blot
(A). Values were plotted using GraphPad Prism. Inhibition of BSE amplification occurred with IC50
values of 171 nM for rVRQ and 366 nM for rARR calculated from 3 separate experiments (B).
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and vCJD.28 This may indicate that VRQ
PrP can effectively interact with PrPSc from
different sources and this may then explain
the inhibitory activity across prion types
with rVRQ acting as a competitive inhibitor.
The reported inhibitory activity of rVRQ
highlights the potential application of recom-
binant PrP proteins as broad-spectrum inhibi-
tors of prion replication. Whether this rVRQ
inhibition of ruminant prion replication
extends to further host species and prion
strains remains to be established.
MATERIAL AND METHODS
Samples
Healthy and diseased ovine tissues were
obtained from the Animal and Plant Health
Agency TSE-Archive (APHA, Addlestone,
Surrey, UK). Classical scrapie infected brain
material was obtained from scrapie positive
specimens submitted to the APHA for testing.
Ovine BSE samples originated from ovine BSE
challenges of sheep performed by the APHA.
The CH1641 scrapie isolate was a gift from
Professor N. Hunter, The Roslin Institute, (Neu-
ropathogenesis Division, University of Edin-
burgh). BSE positive bovine brain samples were
pools of 71 BSE positive cases (SE1929/0749
and SE1945/0035) or were a pool of 4 isolates
(SE1762/0013), all 3 samples were sourced
from the APHA. Apl338ii and G338 scrapie brain
tissue was derived from a transgenic mouse bio-
assay (transgenic for ovine VRQ PRNP) as
described.29 All TSE samples used are detailed
in Table 1. 10% (w/v) brain homogenates were
prepared as described previously.30 Healthy
ovine brain tissue was obtained from a scrapie-
free, New Zealand derived flock (ARSU,
APHA) and bovine brain tissue from a
confirmed BSE negative Fresian cow.
Production of Recombinant PrP Proteins
Prnp genes for ovine PrP VRQ (23–231) and
ARR (23–231) were amplified by PCR from
genomic DNA isolated from sheep of known
FIGURE 6. Inhibition of distinct prion strains/
isolates with rVRQ. All samples were amplified
in duplicate by sPMCA for 5 rounds. Classical
scrapie (genotypes VRQ/ARQ and VRQ/VRQ,
isolates PG1361/05 and PG1563/02, respec-
tively), transgenic-mouse passaged classical
scrapie (2 isolates each of G338 and Apl338/
Apl338ii passaged in mice with genotype VRQ)
and experimental ovine BSE (2 isolates, both
ARQ/ARQ) were amplified using a VRQ/VRQ
PrPC substrate. Experimental CH1641 scrapie
was amplified using an AHQ/AHQ PrPC sub-
strate. Two bovine BSE samples were amplified
using a bovine PrPC substrate. Representative
western blots of PMCA reaction products ampli-
fied in the presence (C) or absence (¡) of
400 nM rVRQ are shown for each TSE type (A).
6.7 mL of PK digested PMCA reaction was ana-
lyzed by western blotting using monoclonal anti-
body SHa31. Following densitometry, signals
were expressed as the percent inhibition, calcu-
lated using the no inhibition controls as 100%
amplification (B). The data in (B) is collated from
2 separate experiments. Molecular mass
markers are indicated.
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genotype using the primers: Ov PrP pET F 50-
AGAATTCATATGAGCAAGAAGCGTCCAA
AACCTGGCGGAGGATG-30 and Ov PrP pET
R 50-ACTCAGGATCCTATCAACTTGCCCCA
CGTTGGTAATAAGCCTGGGATTC-30. Prod-
ucts were digested with NdeI and BamHI and
ligated into plasmid pET22b at NdeI and
BamHI sites. The sequences of the Prnp inserts
were confirmed by Sanger sequencing. The con-
struct for the ovine recombinant protein ARQ
(23–231) in the expression plasmid pET41 (aC)
was obtained from IDEXX Laboratories.
VRQ and ARR recombinant proteins were
expressed in Novablue (DE3) E. coli, and ARQ
recombinant protein was expressed in Top10 E.
coli. Briefly, bacterial cultures were grown in
2YT containing 100 mg/mL ampicillin (VRQ,
ARR) or 50 mg/ml kanamycin (ARQ), and at
mid log growth were induced by addition of
1 mM Isopropyl b-D-1-thiogalactopyranoside.
Cultures were incubated shaking at 378C over-
night. Cells were then harvested by centrifuga-
tion at 2800 g for 30 minutes and stored at
¡208C before lysis. Cell pellets were resus-
pended in lysis buffer (50 mM NaH2PO4,
300 mM NaCl, pH 8.0, 0.1 % Nonidet P-40,
10 mg/mL lysozyme, and Roche complete pro-
tease inhibitor without EDTA) and then incu-
bated at 378C for 1 hour. DNase I (1 mg/mL,
240 mL) and 120 mL MgCl2 (1 M) were added
and incubated at room temperature for
15 minutes. Lysate was centrifuged at 12000 g
for 20 minutes at 48C. The pellets were then
resuspended in 25 mL wash buffer (10 mM
Tris pH 8.0, 0.1 % Nonidet P-40) and incubated
on ice for 20 minutes and pellets recovered by
centrifugation as before. Washing was repeated
3 times. Pellets were resuspended in 2.5 mL
solubilisation buffer (8 M urea, 50 mM
NaH2PO4, 300 mM NaCl, pH 7.5) overnight at
room temperature with rotation. Samples were
centrifuged as before and supernatant purified
by FPLC using an IMAC Hi-Trap chelating
column (5 ml) (GE healthcare) pre-charged
with copper sulfate. Protein was refolded on
the column as described previously31 and then
eluted on a 0–0.5 M imidazole gradient in
300 mM NaCl/50 mM NaH2PO4 (elution
buffer). Protein fractions from the elution peak
were assessed for purity by SDS-PAGE,
staining with Instant Blue (Expedeon). Protein
concentrations were determined by Bradford
assay against a BSA standard. Protein fractions
were pooled and stored at ¡80C with 20 %
(w/v) sucrose. rPrP was used as an inhibitor
directly in PMCA reactions to determine inhib-
itor concentration 50% (IC50) values for inhi-
bition of the classical scrapie PG1361/05. For
subsequent PMCA experiments, imidazole and
sucrose were removed from protein prepara-
tions by 2 rounds of dialysis against PMCA
conversion buffer (50 mM NaCl, 4 mM EDTA
(pH 8), 1% (v/v) Triton X-100, pH 7.4). Protein
concentrations were determined by Bradford
assay.
Protein Misfolding Cyclic Amplification
PMCA reactions were performed as
described previously.32 Briefly, substrate, PrPSc
“spike” and rPrP were combined in clear
0.2 mL PCR tubes (Corning). PMCA was
performed at 378C at a power setting of 190-
200 W in an ultrasonicating water bath (model
3000; Misonix). Sonication was performed for
40 seconds followed by 29 minutes and 20 sec-
onds of incubation, this cycle was repeated for
24 hours. For serial PMCA (sPMCA) experi-
ments, 50 mL of reaction products were then
added to 100 mL of fresh substrate (including
appropriate inhibitors) and 100 mL of this was
used in the subsequent round of PMCA. Reac-
tion products were stored at ¡208C before
analysis. Reactions to determine relative IC50
values were prepared with 88 mL of brain
homogenate substrate and rPrP to a total vol-
ume of 95 mL. For amplification of PG1361/05
only, sucrose was added to a final concentration
of 2% (w/v). The concentration of each rPrP
was adjusted before use by dilution in elution
buffer. PrPSc “spike” (5 mL) was then added.
Reactions were performed in triplicates and run
for a single round of PMCA. IC50 values were
determined for amplification of a classical scra-
pie isolate (PG1361/05) and a bovine BSE iso-
late (SE1762/0013). For scrapie amplification,
concentrations of rPrPs of 50 nM, 100 nM,
200 nM, 400 nM, 800 nM and 1200 nM were
analyzed with amplifications of 1% (w/v)
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scrapie brain homogenate in VRQ/VRQ brain
homogenate substrate. Controls included unin-
hibited PMCA reaction controls without any
inhibitor present and reactions treated with
1200 nM rVRQ as 100% inhibition controls.
For bovine BSE amplification, PMCA was per-
formed using 10% (w/v) BSE brain homoge-
nate (due to lower amplification efficiencies) in
bovine brain homogenate substrate and a dilu-
tion series of 50 nM, 100 nM, 200 nM,
400 nM and 800 nM recombinant proteins. All
triplicates were each analyzed by dot blot in
duplicate and IC50 values were then calculated
using the mean value for each inhibitor concen-
tration. The experiments to determine IC50 val-
ues were repeated 3 times and the mean IC50
value for each inhibitor across all experiments
reported. Western blot analysis of some of the
samples was also performed, analyzing tripli-
cate sPMCA reactions for each inhibitor con-
centration and the IC50 value determined using
a mean values for each condition.
When assessing the inhibition of scrapie iso-
late PG1361/05, PMCA reactions were also
performed in triplicate in the presence of
1200 nM of BSA, non-denatured rVRQ or
rVRQ denatured by heating to 100C for
10 minutes and cooling immediately on ice.
Dialysed VRQ was also tested as an inhibitor
of the amplification of a range of isolates.
Reactions were prepared as described above
using 400 nM of VRQ rPrP only. Reactions
were spiked with 5 mL of 1 % (w/v) brain
homogenate for each isolate, except for
CH1641 isolate J2935, and bovine BSE sam-
ples SE1929/0749 and SE1945/0035 which
were spiked at 5 mL 10% (w/v) homogenate
due to lower amplification efficiencies. All
reactions were performed in duplicate for 5
rounds of sPMCA. For PrPSc detection, 20 mL
of PMCA product was digested with PK and
6.7 mL of PMCA reaction analyzed by western
blotting.
Capture of PrPSc with rVRQ
rVRQ was immobilised to tosylactivated
magnetic beads following the manufacturer’s
instructions (Invitrogen). Briefly, 10 mg of
beads were reacted with 200 mg of rVRQ in
0.1 M borate buffer overnight at 37C with
shaking. Beads were washed 3 times in TBS
and incubated with 33.5 ml of 10% (w/v) brain
homogenate PG1361/05 for 1 hour at room
temperature with rotation. Beads were then
washed 5 times in TBS. An equivalent experi-
ment was performed without any rVRQ. Beads
(150 mg) from these 2 experiments along with
beads that had not been incubated with brain
homogenate were then used to spike duplicate
PMCA reactions. PrPSc amplification was
compared with reactions spiked directly with
5 ml of 1% (w/v) brain homogenate from
PG1361/05.
Western Blots and Dot Blots
PMCA reaction products were digested with
50 mg/mL proteinase K (PK), 0.045% (w/v)
SDS for 1 hour at 37C and then boiled in LDS
loading buffer (Invitrogen). PMCA product
(0.83 mL) was spotted onto nitrocellulose,
blocked with 3% (w/v) milk powder and probed
with the monoclonal antibody SHa31 at a dilu-
tion of 1:40000 in 0.5% (w/v) milk powder and
0.5% (v/v) tween 20 in TBS buffer (50 mM
Tris-HCl pH 8, 150 mM NaCl) (TBST). Bound
antibody was detected with polyclonal goat
anti-mouse-horseradish peroxidase (HRP)
(Dako) at a dilution of 1:20000 in 0.5% (w/v)
milk powder TBST. Membranes were then
incubated with HRP substrate from an EZ-
Chemiluminescence Detection Kit (Geneflow)
and signals detected using a Photek Photon
Counting System. Images were analyzed using
ImageJ software.33 1200 nM rVRQ treated
reactions were measured as background
readings and subtracted from the other signals.
Percent inhibition values were then calculated
relative to the mean intensity of uninhibited
control reactions. Calculated values were plot-
ted using GraphPad Prism and IC50 values
were determined by nonlinear regression, log
inhibitor verses response (variable slope)
model with constraints at 100% and 0%. This
model calculated the IC50 value from the data
and did not assume a sigmoidal relationship.
Some data sets were reanalysed by western
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blots as described previously30 and analyzing
6.7 mL of PMCA product. Prion detection
steps and densitometry analysis were as for dot
blots.
ABBREVIATIONS
BSE Bovine Spongiform Encephalopathy
CJD Creutzfeldt Jakob Disease
PMCA Protein Misfolding Cyclic Amplification
PrP Prion Protein
rPrP recombinant PrP
TSE Transmissible Spongiform Encephalopathy
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